The 340B drug discount program was intended to help low-income and uninsured patients afford medicine, not create lucrative revenue streams for hospital systems in wealthy communities.
asserted
patients → intend → communities
However, without oversight, that is what it has become.
asserted
it → become → oversight
Congress should return the program to its intended purpose by requiring hospitals to show that the program reaches the vulnerable patients it was intended for.
asserted
it → return → patients
The 340B program allows qualifying hospitals and other providers to purchase outpatient drugs at substantial discounts.
asserted
hospitals → allow → discounts
They can then bill insurers, including Medicare, at normal reimbursement rates and retain the difference.
asserted
They → bill → difference
Congress intended those savings to help safety-net providers stretch their resources and expand services for vulnerable patients.
asserted
providers → intend → patients
In practice, federal law does not require hospitals to prove those savings are passed on to patients or even disclose how the resulting revenue is spent.
asserted
revenue → require → patients
Discounted 340B drug purchases reached roughly $81 billion in 2024.
asserted
purchases → reach → 2024
At that scale, Congress should expect something more than assurances from hospitals that the money eventually benefits the people the program was created to help.
asserted
program → expect → people
Once a patient qualifies under the program’s broad rules, an eligible provider can purchase the discounted drug even when the patient has generous commercial insurance.
asserted
patient → qualify → insurance
That makes a wealthy, well-insured patient potentially far more valuable to a 340B hospital than an uninsured patient who cannot pay the full bill.
asserted
who → make → bill
Once a hospital qualifies, individual patients receiving 340B drugs do not have to be low-income or uninsured.
asserted
patients → qualify → drugs
Minnesota’s experiment with 340B transparency shows how large those incentives can become.
asserted
incentives → show → transparency
A state report found participating providers generated roughly $630 million in net 340B revenue, with the overwhelming majority generated by large health systems rather than traditional safety-net providers.
asserted
majority → find → providers
340B expansion increasingly follows affluent patients.
asserted
expansion → follow → patients
A Health Affairs study found that clinics affiliated with hospitals entering the program after 2004 tended to serve wealthier and more heavily insured communities than earlier participants.
asserted
clinics → find → participants
These clinics often operated in higher-income, lower-poverty areas while qualifying for 340B discounts through their ownership or affiliation with an eligible 340B hospital.
asserted
clinics → operate → hospital
Contract pharmacies, outside pharmacies that dispense 340B drugs on behalf of eligible hospitals and other providers, show a similar pattern.
asserted
that → dispense → pattern
After federal policy dramatically expanded their use in 2010, the share of 340B pharmacies located in the lowest-income neighborhoods declined while the share in the highest-income neighborhoods increased.
asserted
share → expand → neighborhoods
Rather than concentrating where vulnerable patients live, expansion increasingly reached affluent communities.
asserted
expansion → concentrate → communities
The problem is compounded by remarkably weak transparency requirements.
asserted
problem → compound → requirements
Federal law generally does not require hospitals to publicly disclose how much net 340B revenue they generate, how many low-income or uninsured patients receive discounted drugs, how much patients save at the pharmacy counter, or where the revenue ultimately goes.
asserted
revenue → require → counter
Hospitals frequently respond that 340B revenue pays for charity care and other valuable community services.
asserted
revenue → respond → care
But if it is, hospitals should be able to demonstrate it.
asserted
hospitals → demonstrate → it
Every participating hospital should be required to publish annual data showing its 340B drug acquisition costs, reimbursements received, net revenue, charity-care spending, patient discounts, and other uses of 340B funds.
asserted
hospital → participate → funds
Hospitals should also report how many low-income and uninsured patients actually received discounted drugs and how much their out-of-pocket costs were reduced.
asserted
costs → report → pocket
Congress should also require hospitals to pass a meaningful portion of 340B savings directly to low-income and uninsured patients.
asserted
Congress → require → patients
A program justified as a way to help vulnerable patients should produce an identifiable benefit for those patients.
asserted
program → justify → patients
Rules governing affiliated “child sites” and contract pharmacies also need to be tightened.
asserted
Rules → govern → sites
An off-campus oncology practice, specialty clinic, or pharmacy in an affluent neighborhood should not automatically receive 340B privileges simply because its corporate parent owns a qualifying hospital miles away.
asserted
parent → receive → hospital
Affiliated sites should have to demonstrate that they actually serve substantial numbers of low-income or uninsured patients before receiving the subsidy.
asserted
they → have → subsidy
Finally, the definition of who counts as a 340B patient needs to be made explicit.
asserted
who → count → patient
The program’s benefits should be directed toward low-income and uninsured patients instead of allowing hospitals to generate large discounts from affluent, well-insured patients.
asserted
hospitals → direct → patients
None of these reforms would prevent hospitals from receiving help for treating vulnerable patients.
asserted
None → prevent → patients
They would simply require the subsidy to follow the patients who need financial assistance.
asserted
who → require → assistance
Institutions benefiting from billions of dollars in federally mandated drug discounts should be able to tell policymakers and the public how that money is spent.
asserted
money → benefit → policymakers
The Aporia
